The President of Colombia, Ivan Duque, has stated that the country's food and drug regulator, the National Institute of Food and Drug Surveillance (Invima), authorised emergency use of Pfizer Inc and BioNTech SE's COVID-19 vaccine on 5 January 2021, Reuters news agency reported on Wednesday.
Colombia now awaits approval for the COVID-19 vaccines produced by AstraZeneca and Johnson & Johnson's pharmaceutical unit Janssen, Duque added.
Reportedly, patients aged 60 and over, or with co-morbidities such as asthma and diabetes, will be among the first in line for vaccines, along with health workers.
Colombia has agreed to buy 10 million doses each of the Pfizer-BioNTech and AstraZeneca COVID-19 vaccines, as well as nine million from Janssen. It has also secured 20 million vaccine doses via the World Health Organisation-backed COVAX mechanism.
According to Colombia's minister of health, the first delivery of 1.7 million Pfizer-BioNTech vaccine doses is expected in February 2021.
Colombia aims to vaccinate 35.7 million of its 50 million inhabitants.
So far, Colombia has reported 1.7 million COVID-19 infections and 44,426 deaths.
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Nanomi BV to acquire ophthalmology specialist VISUfarma BV
AstraZeneca launches online platform to expand patient access to medications
Avant Technologies enters joint venture to advance stem cell-based diabetes treatments
Innovent and Ollin report progress in development of OLN324 (IBI324)
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Ascletis presents ASC30 study results at EASD Annual Meeting
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation